ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

DSMB Recommends Discontinuing Phase III Perifosine Combination Trial

March 29, 2013

Banned Investigator Plans To Resume Clinical Trials Role

August 10, 1990

Letter To The Editor: Prevention Research Requires Rigor And Collaboration.

June 20, 2003

O’Leary Leads RPCI’s OR;

February 8, 2002

NCI Plans Contract To Study Cancer Research Manpower Needs; Epidemiologist State Their Case

October 7, 1977

Final Issue of 1980

December 19, 1980